Cargando…
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
BACKGROUND: We evaluated the expression of human trophoblastic cell-surface marker (Trop-2) and the potential of hRS7 - a humanized monoclonal anti-Trop-2 antibody - as a therapeutic strategy against treatment-refractory human uterine (UMMT) and ovarian (OMMT) carcinosarcoma cell lines. MATERIALS AN...
Autores principales: | Raji, Rhoda, Guzzo, Federica, Carrara, Luisa, Varughese, Joyce, Cocco, Emiliano, Bellone, Stefania, Betti, Marta, Todeschini, Paola, Gasparrini, Sara, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter, Rutherford, Thomas J, Buza, Natalia, Pecorelli, Sergio, Santin, Alessandro D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224774/ https://www.ncbi.nlm.nih.gov/pubmed/22075385 http://dx.doi.org/10.1186/1756-9966-30-106 |
Ejemplares similares
-
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011) -
Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGF(c )chimeric protein targeting tissue factor
por: Cocco, Emiliano, et al.
Publicado: (2011) -
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020) -
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises
uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent
cell cytotoxicity in vitro: implications for trastuzumab-based
immunotherapy
por: Bellone, S, et al.
Publicado: (2012) -
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)